Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, multicenter, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL 103 versus oral comparator in the treatment of community-acquired pneumonia in adults

Next Previous
Trial Profile

A double-blind, multicenter, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL 103 versus oral comparator in the treatment of community-acquired pneumonia in adults

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linopristin/flopristin (Primary) ; Amoxicillin
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Sponsors Novexel

Most Recent Events

  • 12 Sep 2009 Results reported at ICAAC 2009.
  • 11 Sep 2009 Results will be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), according to a Novexel media release.
  • 09 Jan 2009 Planned number of patients changed from 300 to 302, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top